醋酸来法莫林Lefamulin Acetate
【化学名】Lefamulin Acetate
【原研】Nabriva Therapeutics
【上市时间】2021 年 01 月 28 日
【专利到期】2033 年 03 月 18 日
【用途】社区获得性感染，细菌性肺炎，肺炎和社区获得性肺炎; 细菌感染。
【剂型/规格】片剂:600mg/片;注射液：150mg/15mL氯化钠溶液
醋酸来法莫林Lefamulin Acetate
一、 产品概述
Lefamulin Acetate是由Nabriva Therapeutics研发的是一种抗生素，是一种50S核糖体亚基调节剂。2019年08月19日，Lefamulin获得美国食品药品管理局FDA批准，由Nabriva Therapeutics销售，商品名为Xenleta®。
二、主要产品
Description | Structural Formula | CAS No. | Category |
Lefamulin acetate |
| 1350636-82-6 | API |
S-((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-hydroxycyclohexyl) benzothioate |
| 1350636-89-3 | intermediates |
S-((1R,2R,4R)-2-hydroxy-4-(2,2,2-trifluoroacetamido)cyclohexyl) benzothioate |
| 1350636-92-8 | intermediates |
TOS- pleu |
| 31716-01-5 | intermediates |
![G0O_IV(O]M_5@%XII4AQ8D3.png](http://www.mic-pharma.com/public/upload/ueditor/images/20240428/1714287949805276.png "1714287949805276.png")
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.